Crossmark

Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System

Crossref DOI link: https://doi.org/10.1007/s40261-024-01396-6

Published Online: 2024-10-11

Published Print: 2024-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, Zicheng

Guan, Mengying

Liao, Xiaolan https://orcid.org/0000-0001-9110-3934
License Information

Text and Data Mining valid from 2024-10-01

Version of Record valid from 2024-10-01
More Information

Article History

Accepted: 16 September 2024

First Online: 11 October 2024

Declarations

:

: This study does not require ethical approval to use the publicly available and anonymised datasets from the FAERS.

: The authors declare that they have no competing interests related to this study.

: XL Liao and MY Guan initiated the study and developed the research methodology. MY Guan was in charge of standardising the drug terminology and cleaning the data. The data analysis and summarisation were conducted by ZC Yu and XL Liao. All the authors actively participated in the research process and contributed to the manuscript draft.

: No funding was received to conduct this study.

: Not applicable.

: Not applicable.

: All data are available from the corresponding author.

: Not applicable.

Document is current

Any future updates will be listed below